Extended followup indicates daratumumab with bortezomib and dexamethasone for relapsed MM

Delayed infection exposure as a trigger for childhood ALL

Triplet therapy for all comers in the CLL-BAG trial

Disruption of BAFF-BCR crosstalk in CLL

Metabolic adaptations to targeted therapy in FLT3 mutated acute myeloid leukaemia

Safety and efficacy of blinatumomab for acute lymphoblastic leukaemia

Blood thinners a risk with cancer-associated venous thromboembolism

FDG-PET guidance allows substantial chemoreduction in Hodgkin lymphoma

Interim analysis of the JULIET study

Risk and benefit of anti-coagulants for elderly patients with cancer-associated venous thromboembolism

ZUMA 1: CD19 CAR T cells for refractory NHL

400mg imatinib as good as 800mg for 10 year CML survival